DISPOSAL OF NEWBURY MEDICAL CENTRE

RNS Number : 6740T
Workspace Group PLC
26 July 2022
 

26 July 2022

 

WORKSPACE GROUP PLC

 

WORKSPACE ® ANNOUNCES DISPOSAL OF NEWBURY MEDICAL CENTRE

 

Workspace Group PLC ('Workspace'), London's leading provider of flexible offices, is pleased to announce the simultaneous exchange and completion on the disposal of a medical centre in Newbury, an asset from the McKay portfolio acquired in May 2022, for a total of £7.25m.  The sale of the property is at a premium of £1.15m to the March 2022 valuation. 

 

Graham Clemett, Chief Executive Officer of Workspace, commented:

 

"We are pleased to have completed on this first sale from the identified non-core assets in the McKay portfolio. We continue to progress with our disposal programme, targeting completion by December 2022, with the proceeds expected to significantly reduce our LTV and increase the proportion of fixed-rate debt."

 

 

- ENDS -

 

 

For media and investor enquiries, please contact:

 

Workspace Group PLC   

Kate Annakin, Interim Investor Relations Manager  020 7138 3300

 

FGS Global  

Chris Ryall                                                                                                              020 7251 3801

Guy Lamming 

 

 

Notes to Editors

 

About Workspace Group PLC:

 

Established in 1987 and listed on the London Stock Exchange since 1993. We are home to

thousands of businesses, including fast growing and established brands across a wide range of sectors.

 

Workspace is geared towards helping businesses perform at their very best. We provide inspiring, flexible work spaces in dynamic London locations.

 

Workspace (WKP) is a FTSE 250 listed Real Estate Investment Trust (REIT) and a member of the European Public Real Estate Association (EPRA).

 

Workspace® is a registered trademark of Workspace Group Plc, London, UK.

 

LEI: 2138003GUZRFIN3UT430

 

For more information on Workspace, please visit www.workspace.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISBKPBBABKDOOB
UK 100